Functions of the Lyn tyrosine kinase in health and disease

Cell Communication and Signaling

Volumn 10, Issue , 2012, Pages

  Ingley, Evan ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cancer; Immune dysfunction; Leukaemia; Lyn tyrosine kinase; Oncoprotein signaling; Src family kinases

Indexed keywords

BAFETINIB; BCR ABL PROTEIN; CD135 ANTIGEN; DASATINIB; IMATINIB; LAPATINIB; MOLECULAR MARKER; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN KINASE LYN; RETINOIC ACID; STAT5 PROTEIN; SUNITINIB; TRANSCRIPTION FACTOR ETV6; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY PRODUCTION; B CELL LYMPHOMA; BREAST CANCER; CELL GROWTH; CELL SURVIVAL; CELL TRANSFER; CHRONIC MYELOID LEUKEMIA; DRUG POTENTIATION; ENZYME ACTIVITY; ERYTHROPOIESIS; GENE; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; IMMUNE DYSREGULATION; IMMUNOPATHOLOGY; INTRACELLULAR SIGNALING; KIDNEY CANCER; LEUKOPOIESIS; LUNG CANCER; LYN GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SOLID TUMOR;

EID: 84865098491     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-10-21     Document Type: Review

References (112)

1. The protein kinase complement of the human genome. Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S, Science 2002 298 1912 1934 10.1126/science.1075762 12471243
2. Src Family Kinases: regulating their activity, levels and identifying new pathways. Ingley E, Payne CJ, Murphy SV, McCarthy DJ, Schnieder JR, Rossjohn J, Hibbs ML, Acta Biochim Pol 2007 54 9 10
3. Src family kinases, key regulators of signal transduction. Parsons SJ, Parsons JT, Oncogene 2004 23 7906 7909 10.1038/sj.onc.1208160 15489908
4. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Resh MD, Biochim Biophys Acta 1999 1451 1 16 10.1016/S0167-4889(99)00075-0 10446384
5. Structure and regulation of Src family kinases. Boggon TJ, Eck MJ, Oncogene 2004 23 7918 7927 10.1038/sj.onc.1208081 15489910
6. Identification of a duplication of the mouse Lyn gene. Hibbs ML, Stanley E, Maglitto R, Dunn A, Gene 1995 156 175 181 10.1016/0378-1119(95)00022-X 7758954
7. Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus. Yi T, Bolen JB, Ihle JN, Mol Cell Biol 1991 11 2391 2398 2017160
8. SH2 and SH3 domains: elements that control interactions of cytoplasmic signalling proteins. Koch C, Anderson D, Moran M, Ellis C, Pawson T, Science 1991 252 668 674 10.1126/science.1708916 1708916
9. Substrate conformational restriction and CD45-catalysed dephosphorylation of tail tyrosine-phosphorylated Src protein. Wang D, Esselman WJ, Cole PA, J Biol Chem 2002 277 40428 40433 10.1074/jbc.M206467200 12181320
10. G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase. Futami M, Zhu QS, Whichard ZL, Xia L, Ke Y, Neel BG, Feng GS, Corey SJ, Blood 2011 DOI:10.1182/blood-2009-1112-261636
11. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC, Mol Cell 1999 3 629 638 10.1016/S1097-2765(00)80356-1 10360179
12. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J, J Biol Chem 2009 284 284 291 18984583
13. Autophosphorylation of Src and Yes blocks their inactivation by Csk phosphorylation. Sun G, Sharma AK, Budde RJ, Oncogene 1998 17 1587 1595 10.1038/sj.onc.1202076 9794236
14. Effect of autophosphorylation on the catalytic and regulatory properties of protein tyrosine kinase Src. Sun G, Ramdas L, Wang W, Vinci J, McMurray J, Budde RJ, Arch Biochem Biophys 2002 397 11 17 10.1006/abbi.2001.2627 11747305
15. Csk-binding protein mediates sequential enzymatic down-regulation and degradation of Lyn in erythropoietin-stimulated cells. Ingley E, Schneider JR, Payne CJ, McCarthy DJ, Harder KW, Hibbs ML, Klinken SP, J Biol Chem 2006 281 31920 31929 10.1074/jbc.M602637200 16920712
16. Csk-binding protein can regulate Lyn signals controlling cell morphology. Ingley E, Int J Biochem Cell Biol 2009 41 1332 1343 10.1016/j.biocel.2008.12. 001 19124084
17. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A, Okada M, Nature 2000 404 999 1003 10.1038/35010121 10801129
18. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, Scherer J, Shevchenko A, Hilgert I, Cerny J, et al. J Exp Med 2000 191 1591 1604 10.1084/jem.191.9.1591 10790433
19. The SH2 domain containing tyrosine phosphatase-1 down-regulates activation of Lyn and Lyn-induced tyrosine phosphorylation of the CD19 receptor in B cells. Somani AK, Yuen K, Xu F, Zhang J, Branch DR, Siminovitch KA, J Biol Chem 2001 276 1938 1944 11042209
20. Multiple defects in the immune system of lyn-deficient mice, culminating in autoimmune disease. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR, Cell 1995 83 301 311 10.1016/0092-8674(95) 90171-X 7585947
21. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, Dunn AR, Tarlinton DM, J Exp Med 2002 196 1593 1604 10.1084/jem.20020515 12486102
22. Multiple roles of Lyn kinase in myeloid cell signaling and function. Scapini P, Pereira S, Zhang H, Lowell CA, Immunol Rev 2009 228 23 40 10.1111/j.1600-065X.2008.00758.x 19290919
23. The tyrosine kinase network regulating mast cell activation. Gilfillan AM, Rivera J, Immunol Rev 2009 228 149 169 10.1111/j.1600-065X.2008.00742.x 19290926
24. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. Tilbrook PA, Ingley E, Williams JH, Hibbs ML, Klinken SP, EMBO J 1997 16 1610 1619 10.1093/emboj/16.7.1610 9130706
25. Maturation of erythroid cells and erythroleumkemia development are affected by the kinase activity of Lyn. Tilbrook PA, Palmer GA, Bittorf T, McCarthy DJ, Wright MJ, Sarna MK, Linnekin D, Cull VS, Williams JH, Ingley E, et al. Cancer Res 2001 61 2453 2458 11289114
26. Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis. Ingley E, McCarthy DJ, Pore JR, Sarna MK, Adenan AS, Wright MJ, Erber WN, Tilbrook PA, Klinken SP, Oncogene 2005 24 336 343 10.1038/sj.onc.1208199 15516974
27. Lyn associates with the juxtamembrane region of c-kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. Linnekin D, DeBerry CS, Mou S, J Biol Chem 1997 272 27450 27455 10.1074/jbc.272.43.27450 9341198
28. Src-related protein tyrosine kinases in hematopoiesis. Corey SJ, Anderson SM, Blood 1999 93 1 14 9864140
29. The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling. Hibbs ML, Harder KW, Growth Factors 2006 24 137 149 10.1080/08977190600581327 16801133
30. The novel role for lyn in integrin signaling in human disease. Tomkowicz B, Ptasznik A, Curr Signal Transduct Ther 2009 4 59 65 10.2174/ 157436209787048685
31. Lyn tyrosine kinase: accentuating the positive and the negative. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM, Immunity 2005 22 9 18 15664155
32. HS1 interacts with Lyn and is critical for erythropoietin-induced differentiation of erythroid cells. Ingley E, Sarna MK, Beaumont JG, Tilbrook PA, Tsai S, Takemoto Y, Williams JH, Klinken SP, J Biol Chem 2000 275 7887 7893 10.1074/jbc.275.11.7887 10713104
33. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O, Blood 1998 91 3734 3745 9573010
34. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, Clark R, Quilici C, Grail D, Hodgson GS, Dunn AR, Hibbs ML, Immunity 2001 15 603 615 10.1016/S1074-7613(01)00208-4 11672542
35. Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Harder KW, Quilici C, Naik E, Inglese M, Kountouri N, Turner A, Zlatic K, Tarlinton DM, Hibbs ML, Blood 2004 104 3901 3910 10.1182/blood-2003-12-4396 15339845
36. Impairment of N-methyl-D-aspartate receptor-controlled motor activity in LYN-deficient mice. Umemori H, Ogura H, Tozawa N, Mikoshiba K, Nishizumi H, Yamamoto T, Neuroscience 2003 118 709 713 10.1016/S0306-4522(03)00025-3 12710978
37. Lyn is a target gene for prostate cancer: Sequence-based inhibition induces regression of human tumor xenografts. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, Weinstein I, Reuveni H, Ben-Sasson SA, Cancer Res 2004 64 1058 1066 10.1158/0008-5472.CAN-03-2420 14871838
38. A kinase-dead allele of Lyn attenuates autoimmune disease normally associated with Lyn deficiency. Verhagen AM, Wallace ME, Goradia A, Jones SA, Croom HA, Metcalf D, Collinge JE, Maxwell MJ, Hibbs ML, Alexander WS, et al. J Immunol 2009 182 2020 2029 10.4049/jimmunol.0803127 19201855
39. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Barouch-Bentov R, Che J, Lee CC, Yang Y, Herman A, Jia Y, Velentza A, Watson J, Sternberg L, Kim S, et al. Mol Cell 2009 33 43 52 10.1016/j.molcel.2008.12.024 19150426
40. Lyn kinase promotes erythroblast expansion and late-stage development. Karur VG, Lowell CA, Besmer P, Agosti V, Wojchowski DM, Blood 2006 108 1524 1532 10.1182/blood-2005-09-008243 16705093
41. Deficiency of Src family kinases Fgr and Hck results in activation of erythrocyte K/Cl cotransport. De Franceschi L, Fumagalli L, Olivieri O, Corrocher R, Lowell CA, Berton G, J Clin Invest 1997 99 220 227 10.1172/JCI119150 9005990
42. Sequential phosphorylation of protein band 3 by Syk and Lyn tyrosine kinases in intact human erythrocytes: identification of primary and secondary phosphorylation sites. Brunati AM, Bordin L, Clari G, James P, Quadroni M, Baritono E, Pinna LA, Donella-Deana A, Blood 2000 96 1550 1557 10942405
43. Differential effects of quercetin and resveratrol on Band 3 tyrosine phosphorylation signalling of red blood cells. Maccaglia A, Mallozzi C, Minetti M, Biochem Biophys Res Comm 2003 305 541 547 10.1016/S0006-291X(03)00762-9 12763027
44. Lyn kinase is activated following thrombopoietin stimulation of the megakaryocytic cell line B1647. Santini V, Scappini B, Grossi A, Gozzini A, Bonsi L, Pagliai G, Ferrini PR, Bagnara GP, Haematologica 2002 87 1242 1247 12495897
45. Thrombin-induced tyrosine phosphorylation of HS1 in human platelets is sequentially catalyzed by Syk and Lyn tyrosine kinases and associated with the cellular migration of the protein. Brunati AM, Deana R, Folda A, Massimino ML, Marin O, Ledro S, Pinna LA, Donella-Deana A, J Biol Chem 2005 280 21029 21035 10.1074/jbc.M412634200 15795233
46. Translocation of the csk homologous kinase (chk/hyl) controls activity of cd36-anchored lyn tyrosine kinase in thrombin-stimulated platelets. Hirao A, Hamaguchi I, Suda T, Yamaguchi N, EMBO J 1997 16 2342 2351 10.1093/emboj/16.9. 2342 9171348
47. SHIP1 and Lyn Kinase Negatively Regulate Integrin alpha IIb beta 3 signaling in platelets. Maxwell MJ, Yuan Y, Anderson KE, Hibbs ML, Salem HH, Jackson SP, J Biol Chem 2004 279 32196 32204 10.1074/jbc.M400746200 15166241
48. Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. Quek LS, Pasquet JM, Hers I, Cornall R, Knight G, Barnes M, Hibbs ML, Dunn AR, Lowell CA, Watson SP, Blood 2000 96 4246 4253 11110698
49. Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. Kawakami Y, Kitaura J, Satterthwaite AB, Kato RM, Asai K, Hartman SE, Maeda-Yamamoto M, Lowell CA, Rawlings DJ, Witte ON, Kawakami T, J Immunol 2000 165 1210 1219 10903718
50. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. Odom S, Gomez G, Kovarova M, Furumoto Y, Ryan JJ, Wright HV, Gonzalez-Espinosa C, Hibbs ML, Harder KW, Rivera J, J Exp Med 2004 199 1491 1502 10.1084/jem.20040382 15173205
51. Dysregulated FcepsilonRI signaling and altered Fyn and SHIP activities in Lyn-deficient mast cells. Hernandez-Hansen V, Smith AJ, Surviladze Z, Chigaev A, Mazel T, Kalesnikoff J, Lowell CA, Krystal G, Sklar LA, Wilson BS, Oliver JM, J Immunol 2004 173 100 112 15210764
52. Functional analysis of Lyn kinase A and B isoforms reveals redundant and distinct roles in Fc epsilon RI-dependent mast cell activation. Alvarez-Errico D, Yamashita Y, Suzuki R, Odom S, Furumoto Y, Yamashita T, Rivera J, J Immunol 2010 184 5000 5008 10.4049/jimmunol.0904064 20308635
53. Lyn-deficient mice develop severe, persistent asthma: Lyn is a critical negative regulator of Th2 immunity. Beavitt SJ, Harder KW, Kemp JM, Jones J, Quilici C, Casagranda F, Lam E, Turner D, Brennan S, Sly PD, et al. J Immunol 2005 175 1867 1875 16034130
54. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-Kinase/Akt in colon carcinoma cells. Bates RC, Edwards NS, Burns GF, Fisher DE, Cancer Res 2001 61 5275 5283 11431370
55. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, et al. Cancer Res 2010 70 9391 9401 10.1158/0008-5472.CAN-10- 0911 20861192
56. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Stettner MR, Wang W, Nabors LB, Bharara S, Flynn DC, Grammer JR, Gillespie GY, Gladson CL, Cancer Res 2005 65 5535 5543 10.1158/0008-5472.CAN-04-3688 15994925
57. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP, J Invest Med 2001 49 157 165 10.2310/6650.2001.34042
58. Expression of B cell receptor-associated signaling molecules in human lupus. Huck S, Le Corre R, Youinou P, Zouali M, Autoimmunity 2001 33 213 224 10.3109/08916930109008048 11683380
59. Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. Pazdrak K, Olszewska-Pazdrak B, Stafford S, Garofalo RP, Alam R, J Exp Med 1998 188 421 429 10.1084/jem.188.3.421 9687520
60. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. Adachi T, Stafford S, Sur S, Alam R, J Immunol 1999 163 939 946 10395690
61. Lyn kinase controls basophil GATA-3 transcription factor expression and induction of Th2 cell differentiation. Charles N, Watford WT, Ramos HL, Hellman L, Oettgen HC, Gomez G, Ryan JJ, O'Shea JJ, Rivera J, Immunity 2009 30 533 543 10.1016/j.immuni.2009.02.008 19362019
62. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. Tsantikos E, Oracki SA, Quilici C, Anderson GP, Tarlinton DM, Hibbs ML, J Immunol 2010 184 1348 1360 10.4049/jimmunol.0901878 20042579
63. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. Scapini P, Hu Y, Chu CL, Migone TS, Defranco AL, Cassatella MA, Lowell CA, J Exp Med 2010 207 1757 1773 10.1084/jem.20100086 20624892
64. The p54 cleaved form of the tyrosine kinase Lyn generated by caspases during BCR-induced cell death in B lymphoma acts as a negative regulator of apoptosis. Luciano F, Herrant M, Jacquel A, Ricci JE, Auberger P, FASEB J 2003 17 711 713 12586738
65. The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice. Marchetti S, Gamas P, Belhacene N, Grosso S, Pradelli LA, Colosetti P, Johansen C, Iversen L, Deckert M, Luciano F, et al. EMBO J 2009 28 2449 2460 10.1038/emboj.2009.183 19590497
66. Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation. Luciano F, Ricci JE, Auberger P, Oncogene 2001 20 4935 4941 10.1038/sj.onc.1204661 11526478
67. SRC in human carcinogenesis. Russello SV, Shore SK, Front Biosci 2003 8 1068 S1073 10.2741/1138 12957809
68. C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T, Cancer Res 2003 63 5028 5033 12941830
69. Nonreceptor tyrosine kinases in prostate cancer. Chang YM, Kung HJ, Evans CP, Neoplasia 2007 9 90 100 10.1593/neo.06694 17357254
70. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL, N Engl J Med 2001 344 1031 1037 10.1056/NEJM200104053441401 11287972
71. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320 17192538
72. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. N Engl J Med 2007 356 115 124 10.1056/NEJMoa065044 17215529
73. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR, Cancer Res 2010 70 2296 2306 10.1158/0008-5472.CAN-09-3141 20215510
74. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Hu YG, Liu YH, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li SG, Nat Genet 2004 36 453 461 10.1038/ng1343 15098032
75. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ, Leukaemia 1999 13 855 861 10.1038/sj.leu.2401429
76. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M, Blood 2003 101 690 698 10.1182/blood.V101.2.690 12509383
77. Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease. Xiao W, Ando T, Wang HY, Kawakami Y, Kawakami T, Blood 2010 116 6003 6013 10.1182/blood-2010-05- 283937 20858858
78. A critical role for Lyn in acute myeloid leukemia. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C, Blood 2008 111 2269 2279 10.1182/blood-2007-04-082099 18056483
79. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, Pinna LA, Zambello R, Semenzato G, Donella-Deana A, J Clin Invest 2005 115 369 378 15650771
80. Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Tauzin S, Ding H, Khatib K, Ahmad I, Burdevet D, van Echten-Deckert G, Lindquist JA, Schraven B, Din NU, Borisch B, Hoessli DC, Blood 2008 111 2310 2320 10.1182/blood-2007-05-090985 18070987
81. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. Takeda Y, Nakaseko C, Tanaka H, Takeuchi M, Yui M, Saraya A, Miyagi S, Wang C, Tanaka S, Ohwada C, et al. Brit J Haematol 2011 153 589 598 10.1111/j.1365-2141.2011.08663.x
82. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F, Cancer Res 2003 63 375 381 12543790
83. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M, Blood 2003 101 664 672 10.1182/blood-2002- 01-0288 12393636
84. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE, Oncogene 2002 21 8075 8088 10.1038/sj.onc.1206008 12444544
85. Lyn is an important component of the signal transduction pathway specific to FLT3//ITD and can be a therapeutic target in the treatment of AML with FLT3//ITD. Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T, Leukemia 2007 21 403 410 10.1038/sj.leu.2404547 17230226
86. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells. Congleton J, Macdonald R, Yen A, Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2012 26 1180 1188 10.1038/leu.2011.390
87. Src Family Kinases Phosphorylate the Bcr-Abl SH3-SH2 Region and Modulate Bcr-Abl Transforming Activity. Meyn MA, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J, Hochrein JM, Engen JR, Smithgall TE, J Biol Chem 2006 281 30907 30916 10.1074/jbc.M605902200 16912036
88. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronis myelogenous leukemia cells. Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ, Blood 2008 111 3821 3829 10.1182/blood-2007-08-109330 18235045
89. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML, Cell 1993 75 175 185 8402896
90. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB, Oncogene 2009 28 1669 1681 10.1038/onc.2009.7 19234487
91. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM, Nat Med 2004 10 1187 1189 10.1038/nm1127 15502840
92. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Muschen M, et al. Sci Signal 2011 4 a18 10.1126/scisignal.2001314 21447799
93. SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF. Wang B, Lemay S, Tsai S, Veillette A, Mol Cell Biol 2001 21 1077 1088 10.1128/MCB.21.4.1077-1088.2001 11158295
94. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, et al. N Engl J Med 2006 354 2531 2541 10.1056/NEJMoa055229 16775234
95. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A, Curr Opin Investig Drugs 2010 11 1450 1465 21154127
96. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al. Cancer Cell 2009 16 401 412 10.1016/j.ccr.2009.09.028 19878872
97. Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Negro R, Gobessi S, Longo PG, He Y, Zhang ZY, Laurenti L, Efremov DG, Blood 2012 119 6278 6287 10.1182/blood-2012-01-403162 22569400
98. Expression cloning of oligomerization-activated genes with cell-proliferating potency by pseudotype retrovirus vector. Abe A, Emi N, Kanie T, Imagama S, Kuno Y, Takahashi M, Saito H, Naoe T, Biochem Biophys Res Comm 2004 320 920 926 10.1016/j.bbrc.2004.06.040 15240136
99. Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. Tanaka H, Takeuchi M, Takeda Y, Sakai S, Abe D, Ohwada C, Sakaida E, Shimizu N, Saito Y, Miyagi S, et al. Leukemia 2010 24 197 200 10.1038/leu.2009.167 19710703
100. Src in cancer: deregulation and consequences for cell behaviour. Frame MC, Biochim Biophys Acta 2002 1602 114 130 12020799
101. Characteristics of virus-specific RNA in avian sarcoma virus-transformed BHK-21 cells and revertants. Deng CT, Stehelin D, Bishop JM, Varmus HE, Virology 1977 76 313 330 10.1016/0042-6822(77)90305-1 189495
102. Activating SRC mutation in a subset of advanced human colon cancers. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ, Nat Gen 1999 21 187 190 10.1038/5971
103. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, et al. Nat Biotechnol 2009 27 77 83 10.1038/nbt.1513 19098899
104. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES, Mol Cancer Ther 2008 7 1807 1816 10.1158/1535-7163.MCT-08-0058 18644993
105. Functional analysis of Csk and CHK kinases in breast cancer cells. Bougeret C, Jiang SX, Keydar I, Avraham H, J Biol Chem 2001 276 33711 33720 10.1074/jbc.M104209200 11445575
106. Comparative tyrosine-kinase profiles in colorectal cancers: Enhanced arg expression in carcinoma as compared with adenoma and normal mucosa. Chen WS, Kung HJ, Yang WK, Lin WC, Int J Cancer 1999 83 579 584 10.1002/(SICI)1097- 0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R 10521789
107. CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Subramaniam V, Vincent IR, Gardner H, Chan E, Dhamko H, Jothy S, Exp Mol Pathol 2007 83 207 215 10.1016/j.yexmp.2007.04.008 17599831
108. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM, J Clin Invest 2000 106 1399 1407 10.1172/JCI10536 11104793
109. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE, Cancer Res 2008 68 3323 3333 10.1158/0008-5472.CAN-07-2997 18451159
110. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA, Witte ON, Proc Natl Acad Sci USA 2011 108 6579 6584 10.1073/pnas.1103904108 21464326
111. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. Ding Q, Stewart J, Olman MA, Klobe MR, Gladson CL, J Biol Chem 2003 278 39882 39891 10.1074/jbc.M304685200 12881526
112. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Brenton JD, Carey LA, Ahmed AA, Caldas C, J Clin Oncol 2005 23 7350 7360 10.1200/JCO.2005.03.3845 16145060